Graph takes few seconds to load...
Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutations across a range of tumor types, and which affect the epidermal growth factor receptor (EGFR), the tyrosine-protein kinase, or human epidermal growth factor receptor 2.
The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including allosteric and canonical EGFR mutations; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases.
The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
| Annual Data | Millions of US $ except per share data |
|---|
| Cash on hand |
| Receivables |
| Inventory |
| Pre-Paid Expenses |
| Other Current Assets |
| Total Current Assets |
| Property, Plant, And Equipment |
| Long-Term Investments |
| Goodwill And Intangible Assets |
| Other Long-Term Assets |
| Total Long-Term Assets |
| Total Assets |
| Total Current Liabilities |
| Long Term Debt |
| Other Non-Current Liabilities |
| Total Long Term Liabilities |
| Total Liabilities |
| Common Stock Net |
| Retained Earnings (Accumulated Deficit) |
| Comprehensive Income |
| Other Share Holders Equity |
| Share Holder Equity |
| Total Liabilities And Share Holders Equity |
